Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Updates 2005 Part B Payment Rates; Gemzar ASP Increases By 7.3%

Executive Summary

Lilly has reversed a 7% price cut for the oncologic Gemzar ahead of the 2005 transition to average sales price-based reimbursement under Medicare Part B

You may also be interested in...



Energy & Commerce Health Chairman Deal Brings Medicaid Background

Rep. Nathan Deal (R-Ga.) brings Medicaid expertise to his new role as House Energy & Commerce Health Subcommittee chairman

Energy & Commerce Health Chairman Deal Brings Medicaid Background

Rep. Nathan Deal (R-Ga.) brings Medicaid expertise to his new role as House Energy & Commerce Health Subcommittee chairman

Part B Average Sales Price Drug Rates Finalized; Zoladex Down 12%

AstraZeneca's prostate cancer therapy Zoladex will be reimbursed at 12% below CMS' previously estimated rate when payment changes for Medicare Part B-covered drugs take effect Jan. 1

Related Content

UsernamePublicRestriction

Register

PS044930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel